Immunotherapy + Radiotherapy for Lung Cancer
(SPRINT 2 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the effectiveness and safety of two combinations of immunotherapy drugs paired with personalized radiotherapy for treating locally advanced non-small cell lung cancer (NSCLC). Participants will receive either durvalumab with monalizumab or durvalumab with oleclumab, followed by radiotherapy. Those with NSCLC and a high PD-L1 tumor proportion score, indicating potential responsiveness to immunotherapy, who have not yet undergone treatment for stage II or III cancer, might be suitable candidates. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of participants.
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you need to stop your current medications. However, you cannot take any concurrent chemotherapy, biologic, or hormonal therapy for cancer treatment during the trial.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Previous studies have shown positive safety results for the durvalumab and monalizumab combination. Research indicates that patients generally tolerate this combination well. Common side effects, such as tiredness and nausea, were reported but were usually manageable.
For the durvalumab and oleclumab combination, studies also indicate a manageable safety profile. Side effects can occur, but they are often similar to those expected from immune-boosting treatments.
Both combinations aim to strengthen the immune response against lung cancer. Participants in earlier studies generally handled these treatments well, with manageable side effects.12345Why are researchers excited about this trial's treatments?
Researchers are excited about these treatments for lung cancer because they combine immunotherapy with radiotherapy, potentially enhancing the effectiveness of both. Durvalumab and Monalizumab work together by blocking proteins that help cancer cells evade immune detection, boosting the body's ability to fight the cancer. Meanwhile, the combination of Durvalumab with Oleclumab targets different pathways, potentially disrupting the tumor's blood supply and immune evasion strategies. These innovative combinations aim to increase the precision and potency of cancer treatment, offering hope for improved outcomes compared to traditional chemotherapies and radiation alone.
What evidence suggests that this trial's treatments could be effective for lung cancer?
This trial will evaluate the effectiveness of combining durvalumab with either monalizumab or oleclumab for treating non-small cell lung cancer (NSCLC). Research has shown that patients who took durvalumab with oleclumab had a 64.8% chance of their cancer not growing or spreading for at least 10 months. In contrast, those who took durvalumab with monalizumab had a 72.7% chance. These findings suggest these combinations might help stop tumor growth and possibly extend the time patients live without their cancer worsening. Both treatments were generally well-tolerated, causing few severe side effects. Overall, these combinations could offer new options for people with advanced NSCLC.23678
Who Is on the Research Team?
Nitin R Ohri, MD
Principal Investigator
Montefiore Medical Center
Are You a Good Fit for This Trial?
This trial is for people with advanced non-small cell lung cancer (NSCLC) who have a high PD-L1 tumor score (at least 50%). Participants will be randomly assigned to one of two immunotherapy combinations and receive tailored radiotherapy.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Induction Immunotherapy
Participants receive two cycles of dual-agent immunotherapy with durvalumab and either monalizumab or oleclumab
Radiotherapy
Participants undergo a four-week course of risk-adapted, dose-painted radiotherapy
Consolidation Immunotherapy
Participants receive up to ten cycles of dual-agent immunotherapy with durvalumab and either monalizumab or oleclumab
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Durvalumab
- Monalizumab
- Radiotherapy
Trial Overview
The study tests the effectiveness and safety of combining durvalumab with either monalizumab or oleclumab, followed by personalized radiotherapy. The goal is to see which combination works best for NSCLC patients.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Durvalumab 1500 mg IV on day 1 and oleclumab 3000 mg IV on day 1 and 15 of a 28-day cycle for two cycles, followed by four weeks risk adapted, dose-painted radiotherapy, followed by durvalumab 1500 mg and oleclumab 3000 mg on day 1 of 28-day cycles for up to ten cycles.
Durvalumab 1500 mg IV and monalizumab 1500 mg IV on day 1 of a 28-day cycle for two cycles, followed by four weeks of risk adapted, dose-painted, radiotherapy, followed by durvalumab 1500 mg IV and monalizumab 1500 mg IV on day 1 of 28-day cycle for up to ten cycles.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Montefiore Medical Center
Lead Sponsor
AstraZeneca
Industry Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Citations
Durvalumab Alone or Combined With Novel Agents for ...
This randomized clinical trial reports the objective response rate, progression-free survival, overall survival, and safety profile of ...
Updated results from COAST, a phase 2 study of ...
Key secondary endpoints: safety, PFS, and overall survival (OS). Results: From Jan 2019 to Jul 2020, 186 of 189 randomized pts received ...
PACIFIC-9: Phase III trial of durvalumab + oleclumab or ...
Studies show that durvalumab lowers the risk of cancer growing or spreading, and prolongs survival, when administered after chemotherapy and ...
4.
mdanderson.org
mdanderson.org/newsroom/research-newsroom/pre-surgical-combination-therapy-shows-promising-results-for-nsclc.h00-159776445.htmlPre-surgical combination therapy shows promising results ...
Overall, the combinations were well tolerated and had no adverse impacts on surgery. The results highlight the potential benefits of adding ...
5.
innate-pharma.com
innate-pharma.com/media/all-press-releases/monalizumab-data-neocoast-2-phase-2-study-early-stage-nsclc-presented-wclc-2024Monalizumab data from NeoCOAST-2 Phase 2 study in early ...
The NeoCOAST-2 platform study is intended to assess the safety and efficacy of neoadjuvant durvalumab alone or combined with novel agents and chemotherapy.
Phase 1/2 study of monalizumab plus durvalumab in ...
Though the safety profile of monalizumab combination therapy is clinically favorable and the translational data support immune activation ...
NeoCOAST-2 Data Shows Combination of Durvalumab ...
Phase 2 results from the NeoCOAST-2 study demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete response ...
A phase II study of monalizumab and durvalumab in ...
In lung cancer, the addition of M to D has shown improved progression-free survival (PFS) for unresectable stage III non-small-cell lung cancer (NSCLC) and ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.